Assessing Nirmatrelvir-Ritonavir Combination in SARS-CoV-2 Treatment for Vaccinated and Unvaccinated Patients
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on April 24th, 2024
|
Currently, the antiviral combination of nirmatrelvir and ritonavir are widely used to treat SARS-CoV-2 infection. While the efficacy of this drug has been evaluated in unvaccinated adults, its efficacy rate in a population comprising both vaccinated and unvaccinated individuals remains uncertain. A recent study, featured in the New England Journal of Medicine, investigated the interplay between nirmatrelvir and SARS-CoV-2 vaccination.
The research involved 1296 patients diagnosed with SARS-CoV-2 infection via either RT-PCR test or rapid antigen detection test within 5 days of symptom onset. The average age of participants was 42 years, with approximately 57% having received COVID-19 vaccination. Following enrollment, patients were randomly assigned to receive either placebo or the nirmatrelvir-ritonavir combination (300 mg nirmatrelvir and 100 mg ritonavir) every 12 hours for 5 days. After an average follow-up period of 27 days, findings indicated no significant difference in hospitalization risk or recovery time between placebo and the nirmatrelvir-ritonavir combination.
The research involved 1296 patients diagnosed with SARS-CoV-2 infection via either RT-PCR test or rapid antigen detection test within 5 days of symptom onset. The average age of participants was 42 years, with approximately 57% having received COVID-19 vaccination. Following enrollment, patients were randomly assigned to receive either placebo or the nirmatrelvir-ritonavir combination (300 mg nirmatrelvir and 100 mg ritonavir) every 12 hours for 5 days. After an average follow-up period of 27 days, findings indicated no significant difference in hospitalization risk or recovery time between placebo and the nirmatrelvir-ritonavir combination.